ALK and non-small cell lung carcinoma: The IMMUNOTARGET registry shows that the activity of immunotherapy (IO) in ALK+ NSCLC is poor: in 23 patients with ALK+ NSCLC, none responded to IO with mPFS of 3.1 months.